



*vaccines*



an Open Access Journal by MDPI

## SARS-CoV-2 Variants: Unraveling Vaccines and Immune Responses

Guest Editor:

**Dr. Zijun Wang**

Laboratory of Molecular  
Immunology, The Rockefeller  
University, New York City, NY, USA

Deadline for manuscript  
submissions:

**closed (31 March 2024)**

### Message from the Guest Editor

This Special Issue explores the relationship between SARS-CoV-2 variants, vaccine development, and the immune system. We encourage submissions on genomic, molecular, and structural features of SARS-CoV-2 variants and their implications for vaccine effectiveness. We also seek studies on immune response dynamics in the context of these variants. Potential topics of interest include, but are not limited to: 1. Comprehensive characterization of emerging SARS-CoV-2 variants and their unique features; 2. Evaluation of the effectiveness of currently available vaccines against variant strains; 3. Analysis of the immune response elicited by vaccines targeting SARS-CoV-2 variants; 4. Investigation of variant-specific immune evasion mechanisms and their impact on breakthrough infections; 5. Long-term durability and persistence of vaccine-induced immunity against variant strains; 6. Assessment of alternative vaccination strategies or booster doses to address variant challenges; 7. Understanding the implications of SARS-CoV-2 variants on global vaccination efforts and public health interventions; 8. Real-world effectiveness studies of vaccines against variant strains in diverse populations.



[mdpi.com/si/176211](https://mdpi.com/si/176211)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)